Survodutide — compound monograph
Dual glucagon and GLP-1 receptor agonist (acylated). Phase 3. The Institute assesses 3 outcomes for this compound and grades the strongest at moderate certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Survodutide
- Compound class
- Dual glucagon and GLP-1 receptor agonist (acylated)
- Assessment series
- Incretin receptor agonists
- Synonyms and codes
- BI 456906 · survodutide (INN)
- Route as evaluated
- Subcutaneous once weekly
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 2260808-11-9
- Molecular formula
- not published in full
- Average mass
- ≈4700 (approximate)
- Monoisotopic mass
- not published
- ATC classification
- not assigned
§1.3Sequence and structural notes
Unlike tirzepatide and retatrutide, which are built on the GIP scaffold, survodutide is built on glucagon. The engineering objective is a glucagon-to-GLP-1 potency ratio that delivers energy expenditure and hepatic benefit without net glycaemic deterioration.
§1.4Assessment status
The Institute assesses Survodutide across 3 indications and grades the strongest of them at moderate certainty. In confirmatory clinical development; no marketing authorisation.
Table 1. Assessed outcomes for Survodutide, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Obesity and overweight in adults | −14.9 % body weight at 46 weeks with 6.0 mg in phase 2 versus −2.8 % with placebo | Moderate | 3 |
| Metabolic dysfunction-associated steatohepatitis | Histological improvement in fibrosis without worsening of steatohepatitis in 34.5 % at 4.8 mg versus 22.4 % with placebo at 48 weeks | Low | 2 |
| Type 2 diabetes mellitus | −1.7 % HbA1c at 16 weeks in phase 2 | Low | 1 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.